NEW YORK--(BUSINESS WIRE)--IntelliCell BioScience, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“IntelliCell”) or the (“Company”), A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Summerfeldt’s budding basketball career was saved through Dr. Anthony Maddalo’s treatment using IntelliCell BioSciences proprietary SVF Cells (Stem Cell Therapy). Mr. Summerfeldts, a former star player for the Norwegian National Basketball Team, had undergone six knee surgeries and lived in constant pain. He had forfeited his Wake Forest basketball scholarship. Manhattan College took a chance on him and invited him to join their team. Due solely to the two IntelliCell SVF (Stem Cell) treatments in New York City by Dr. Maddalo near the end of 2010 and the beginning of 2011, he started his first game for Manhattan College pain free on January 20, 2012.
Dr. Steven Victor, CEO of IntelliCell BioSciences, said “We are very proud that our proprietary technology used by Dr. Maddalo was able to rehabilitate Torgims’s knees and alleviate his pain. Sports related injuries are a predominate focus for our Company. Doctors using our proprietary technology have treated several professional and college athletes with excellent results. Patients have seen cartilage regrow in the knee. We are about to start a multi-center study for several sports injury indications at major centers. We are fortunate to have several top orthopedic surgeons on our advisory board such as; Dr. Andrews, Dr. Hackel, Dr. Dugas and Dr. Nicola. We believe the 2012–2013 years will see significant revenues from the use of our technology to treat athletes. We believe that this is a $1.3 billion market opportunity just in the United States.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioScience in exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.